NCT04948398No Longer Available不适用
Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
研究设计
- 研究类型
- Expanded Access
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Temporarily Not Available
不适用
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)Warm Autoimmune Hemolytic AnemiaNCT05221619Janssen Research & Development, LLC
Available
不适用
Expanded Access to Gallium Maltolate (GaM)Refractory GlioblastomaGlioblastoma MultiformeGlioblastomaNCT06404034Imaging Biometrics, LLC
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelLarge B-cell LymphomaFollicular LymphomaNCT05776160Kite, A Gilead Company
进行中（未招募）
3 期
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's DiseaseCrohn DiseaseNCT05197049Janssen Research & Development, LLC350
Available
不适用
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAcute Lymphoblastic LeukemiaMantle Cell LymphomaNCT05776134Kite, A Gilead Company